Loading stock…

Cipla Limited (CIPLA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Cipla Limited

CIPLAMarket cap $11BPrice $13.9

Country🇮🇳India

SectorHealthcare

IndustryPharmaceuticals

Manufactures generic drugs and inhalers that treat respiratory illness, HIV, and cancer across 80+ countries. It's one of the world's largest asthma inhaler makers, keeping breathing medicine affordable from Mumbai to Johannesburg.

In Bastion Portfolios?

52W Return-23%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+3%4

Revenue Forecast

Rev CAGR (1y)+8%5

Rev CAGR (3y)+11%7

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1+3%4

EPS Growth Y+2+24%8

EPS Growth Y+3+13%7

Quality

Margins

EBIT Margin15%6

Net Income Margin12%6

Free Cash Flow Margin8%5

Debt

Net Debt/EBITDA-1.810

Efficiency

ROE10%5

ROAna–

Earnings Stability77

GEAR+AVERAGE65

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)243

P/E Ratio (Forward 3y)193

P/BV3.15

EV Multiples

EV/EBITDA Fwd173

EV/EBIT Fwd214

Yield

Free Cash Flow Yield2.2%4

Dividend Yield1.0%3

Momentum

Short term

1 month return-4%5

3 month return-8%4

YTD return-11%3

Mid term

Price vs 52wHigh81%5

1 year return-11%3

Long term

3 year return+18%4

5 year return+52%6

Risk Shield

Price Risk

Beta0.29

Volatility21%9

Free Cash Flow

Free Cash Flow Margin8%5

Free Cash Flow Yield2.2%4

Quality

ROCE24%9

Earnings Stability77

Net Debt/EBITDA-1.810

02Growth

Is it actually growing, and how fast?

CIPLACipla

Revenue FY26$3.0B

GROWTH RATING↗

AVERAGE57 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+3%4

EPS growth, FY28E+24%8

EPS growth, FY29E+13%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 3%/yr over the last 3 years and is set to grow 11%/yr from here.

Earnings are set to grow in step with sales (EPS about 13%/yr vs revenue 11%/yr).

WATCH

A mid-pack grower, ahead of 57% of companies worldwide.

Revenue is set to grow 11%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's speeding up.

03Price Momentum

Is the market behind it right now?

CIPLACipla

Total return Current62.2%

Price return Current51.8%

MOMENTUM RATING↗

WEAK32 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return-8%4

YTD return-11%3

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return-11%3

3-year return+18%4

5-year return+52%6

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+18% over three years and +52% over five), roughly average for the market.

It's down 11% over the past year, now 19% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over the past month (-4%) and over three months (-8%).

WEAKNESSES

The stock is underperforming so far this year (-11%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the stock is underperforming so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Cipla. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CIPLACipla

Revenue FY26$3.0B

GROWTH RATING↗

AVERAGE57 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+3%4

EPS growth, FY28E+24%8

EPS growth, FY29E+13%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 3%/yr over the last 3 years and is set to grow 11%/yr from here.

Earnings are set to grow in step with sales (EPS about 13%/yr vs revenue 11%/yr).

WATCH

A mid-pack grower, ahead of 57% of companies worldwide.

Revenue is set to grow 11%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's speeding up.

03Price Momentum

Is the market behind it right now?

CIPLACipla

Total return Current62.2%

Price return Current51.8%

MOMENTUM RATING↗

WEAK32 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return-8%4

YTD return-11%3

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return-11%3

3-year return+18%4

5-year return+52%6

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+18% over three years and +52% over five), roughly average for the market.

It's down 11% over the past year, now 19% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over the past month (-4%) and over three months (-8%).

WEAKNESSES

The stock is underperforming so far this year (-11%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Cipla. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community